Abstract:The growing use of molecular imaging helps to control and monitor dosage for increased safety and effectiveness. Molecular imaging agents become the scientific tools for moving a concept from bench work to clinic product development. This special issue provides original research and review of new trends in molecular imaging agent development. Among clinic molecular imaging modalities, radionuclide imaging technique is the most sensitive and could provide target-specific information. The radiotracer could non-invasively assess disease treatment endpoints which used to rely almost exclusively on biopsies and histopathological assays. L.-H. Shen et al. (Taiwan) reviewed molecular imaging in the diagnosis and management of CNS disorders. F.-L. Kong et al. (USA), N. Tsao et al. (USA), and C.-L. Ho et al. (Taiwan) report pharmacokinetics and dosimetry of molecular imaging compounds in oncology. M.-H. Liao et al. (Taiwan), X. Wang et al. (China), C. Wu et al. (China) and M. Tian et al. (USA) reported that molecular imaging techniques play a major role in the development of novel therapies since they measure target expressions (apoptosis, glycolysis) as well as function, pathway activities, and cell migration in the intact organism. Y.-F. Wang et al. and M.-Y. Chao et al. (Taiwan) described the kit probe for 99mTc-labeling which is crucial for centralized drug process. The kit probe may allow theranostic concept. A theranostic agent would be more accurate in the evaluation of patient response to treatment. The radiotracer could also be used for radionuclide therapy as reported by C. Wang et al. (China). Hybrid molecular imaging modalities (PET/CT, SPECT/CT) provide high-sensitivity functional and high-resolution anatomical imaging which are important in design-personalized treatment. M.-C. Chen et al. (Taiwan) reported the value of using I-131 NP-59 SPECT/CT to diagnose patients with subclinical or atypical features of primary aldosteronism. To proof of concept for molecular biology findings using different imaging modalities (optical, sonography) were described by Z. Pu et al. (China). In summary, molecular imaging enables the comprehensive characterization of therapeutic intervention and can be used in preclinical studies, pharmacokinetic studies, dose-finding studies, and proof-of-concept studies. Molecular imaging technologies promote the discovery and development of personalized medicine. Hong Zhang Mei Tian Carrio Ignasi Zhen Cheng Lie-Hang Shen David J. Yang

Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors.

Somatostatin Receptor Based Imaging and Radionuclide Therapy

Molecular Imaging and Therapy for Neuroendocrine Tumors

Clinical research progress of somatostatin receptor imaging agents in neuroendocrine tumors

Diagnostics of neuroendocrine tumours

Theranostics in Neuroendocrine Tumors: Updates and Emerging Technologies

Theranostics in Neuroendocrine Tumors

Application of Molecular Probes in Nuclear Imaging of Neuroendocrine Tumors

Radiolabeled Somatostatin Analogs for Cancer Imaging

Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects

Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients

Somatostatin receptor‐linked α‐particle therapy in neuroendocrine tumours

Somatostatin Receptor Imaging with [18F]FET-{beta}AG-TOCA PET/CT and [68Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study

Somatostatin receptor PET beyond the neuroendocrine tumors of the gastrointestinal tract - the review of literature

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

The Impact of Somatostatin Receptor–Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis

Improved Personalised Neuroendocrine Tumours’ Diagnosis Predictive Power by New Receptor Somatostatin Image Processing Quantification

Molecular Image-Guided Theranostic and Personalized Medicine 2013

State-of-the-Art Hybrid Imaging of Neuroendocrine Neoplasms

Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms by Nuclear Medicine: Update and Future Perspective

Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy